Filtered By:
Specialty: Research
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 3346 results found since Jan 2013.
Therapeutics of Extracellular Vesicles in Cardiocerebrovascular and Metabolic Diseases
Adv Exp Med Biol. 2023;1418:187-205. doi: 10.1007/978-981-99-1443-2_13.ABSTRACTExtracellular vesicles (EVs) are nanoscale membranous vesicles containing DNA, RNA, lipids, and proteins, which play versatile roles in intercellular communications. EVs are increasingly being recognized as the promising therapeutic agents for many diseases, including cardiocerebrovascular and metabolic diseases, due to their ability to deliver functional and therapeutical molecules. In this chapter, the biological characteristics and functions of EVs are briefly summarized. Importantly, the current state of applying EVs in the prevention and tr...
Source: Advances in Experimental Medicine and Biology - August 21, 2023 Category: Research Authors: Zhitao Hou Yiyan Lin Xinyu Yang Jing Chen Guoping Li Source Type: research
Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
CONCLUSIONS: Patients with NVAF who abandoned the first DOAC fill had significantly higher risk of ischemic stroke/SE compared to patients who continued therapy beyond the first fill. There is an unmet need for better access to DOACs so that the long-term risk of poor outcomes may be minimized.PMID:37589313 | DOI:10.1080/03007995.2023.2247967
Source: Current Medical Research and Opinion - August 17, 2023 Category: Research Authors: Mark J Alberts Maryia Zhdanava Dominic Pilon Gabrielle Caron-Lapointe Patrick Lefebvre Brahim Bookhart Akshay Kharat Source Type: research
Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials
CONCLUSION: Despite challenges, observational methods and real-world data can be leveraged in certain important situations for a more timely evaluation of drug effectiveness and safety in more diverse and representative patient populations.PMID:37589143 | DOI:10.1177/17407745231193137
Source: Clinical Trials - August 17, 2023 Category: Research Authors: Joshua D Wallach Yihong Deng Eric C Polley Sanket S Dhruva Jeph Herrin Kenneth Quinto Charu Gandotra William Crown Peter Noseworthy Xiaoxi Yao Molly Moore Jeffery Timothy D Lyon Joseph S Ross Rozalina G McCoy Source Type: research
Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
CONCLUSIONS: Patients with NVAF who abandoned the first DOAC fill had significantly higher risk of ischemic stroke/SE compared to patients who continued therapy beyond the first fill. There is an unmet need for better access to DOACs so that the long-term risk of poor outcomes may be minimized.PMID:37589313 | DOI:10.1080/03007995.2023.2247967
Source: Current Medical Research and Opinion - August 17, 2023 Category: Research Authors: Mark J Alberts Maryia Zhdanava Dominic Pilon Gabrielle Caron-Lapointe Patrick Lefebvre Brahim Bookhart Akshay Kharat Source Type: research
Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials
CONCLUSION: Despite challenges, observational methods and real-world data can be leveraged in certain important situations for a more timely evaluation of drug effectiveness and safety in more diverse and representative patient populations.PMID:37589143 | DOI:10.1177/17407745231193137
Source: Clinical Trials - August 17, 2023 Category: Research Authors: Joshua D Wallach Yihong Deng Eric C Polley Sanket S Dhruva Jeph Herrin Kenneth Quinto Charu Gandotra William Crown Peter Noseworthy Xiaoxi Yao Molly Moore Jeffery Timothy D Lyon Joseph S Ross Rozalina G McCoy Source Type: research
Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
CONCLUSIONS: Patients with NVAF who abandoned the first DOAC fill had significantly higher risk of ischemic stroke/SE compared to patients who continued therapy beyond the first fill. There is an unmet need for better access to DOACs so that the long-term risk of poor outcomes may be minimized.PMID:37589313 | DOI:10.1080/03007995.2023.2247967
Source: Current Medical Research and Opinion - August 17, 2023 Category: Research Authors: Mark J Alberts Maryia Zhdanava Dominic Pilon Gabrielle Caron-Lapointe Patrick Lefebvre Brahim Bookhart Akshay Kharat Source Type: research
Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials
CONCLUSION: Despite challenges, observational methods and real-world data can be leveraged in certain important situations for a more timely evaluation of drug effectiveness and safety in more diverse and representative patient populations.PMID:37589143 | DOI:10.1177/17407745231193137
Source: Clinical Trials - August 17, 2023 Category: Research Authors: Joshua D Wallach Yihong Deng Eric C Polley Sanket S Dhruva Jeph Herrin Kenneth Quinto Charu Gandotra William Crown Peter Noseworthy Xiaoxi Yao Molly Moore Jeffery Timothy D Lyon Joseph S Ross Rozalina G McCoy Source Type: research
Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis
ConclusionThe Enterprise stent can be safely and efficaciously applied in the treatment of symptomatic severe posterior circulation atherosclerotic stenosis, with a relatively low rate of in-stent restenosis and recurrent stroke within 1 year. The stenotic length was the only significant independent risk factor for 1 year stroke or death events and in-stent restenosis.
Source: European Journal of Medical Research - August 17, 2023 Category: Research Source Type: research
Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies
CONCLUSIONS: This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States.PMID:37584187 | DOI:10.1080/03007995.2023.2247988
Source: Current Medical Research and Opinion - August 16, 2023 Category: Research Authors: William L Baker Matthew S Roberts Youssef Bessada Kimberly S Caroti Veronica Ashton Brahim K Bookhart Craig I Coleman Source Type: research
